Compare Invesco Ltd. (IVZ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Recursion Pharmaceuticals Inc — how do they compare? Invesco Ltd. trades at $31.52 (market cap $13.85B), while Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B). The key difference: Invesco Ltd. is far larger — about 7.7× Recursion Pharmaceuticals Inc's market cap, and Invesco Ltd. pays a 2.74% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| IVZ | RXRX | |
|---|---|---|
Market Cap | $13.85B | $1.81B |
Sector | Financials | Health |
52-Week High | $32.01 | $6.79 |
52-Week Low | $20.67 | $2.84 |
Enterprise Value | $24.01B | $1.33B |
Dividend Yield | 2.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Invesco (IVZ) trades at $31.52, down 0.69% today, near its consensus price target of $32.50. The stock shows a bullish technical signal with moving averages supporting an uptrend, while recent earnings have been mixed with Q2 2026 beating expectations. Revenue grew to $6.38 billion in 2025, though net income was negative. Analyst sentiment is balanced with 12 buy and 16 hold ratings, and the company maintains a stable dividend.
The outlook for IVZ hinges on sustained asset under management growth and expense control to return to profitability. Key risks include market volatility affecting AUM and competitive pressures. Upside potential exists if operational improvements continue, but investors face uncertainty from inconsistent earnings performance.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
